Covalab and partners receive €1.06M EUREKA Eurostars grant to develop new combination therapy for glioblastoma

20 September 2022

Covalab and partners CimCure, Amsterdam UMC and the University of Zurich join forces on this project with total public and private fundings of €2.24M, including the Eurostars grant, to develop novel immunotherapy combining CAR-T cells and CimCure’s iBoost vaccines to treat glioblastoma

Bron, France, September 20, 2022 – Covalab, a biotechnology company that specializes in the development and production of recombinant proteins and antibodies for diagnostics and therapeutics, today announces that together with CimCure, a Dutch biotech company focusing on the development of a novel vaccine-based immunotherapy, Amsterdam UMC (The Netherlands) and the University of Zurich (Switzerland), they have received a €1.06M ($1.08M) grant from EUREKA Eurostars. With a total budget of €2.24M ($2.28M,) including investments from the partners, the project aims to develop a new treatment against glioblastoma. CimCure B.V. is the lead coordinator of the project.

To know more